Core Viewpoint - The company, Jindalai (688057.SH), is optimistic about the development prospects of medical robotics technology and plans to optimize its industrial structure to enhance risk resistance and cultivate new profit growth points through a strategic investment in Zhongke Hongtai Medical Technology Co., Ltd. [1] Group 1: Investment Details - The company intends to invest 30 million yuan in Zhongke Hongtai, with 1.9586895 million yuan allocated for subscribing to the new registered capital and the remaining 28.0413105 million yuan added to capital reserves [1] - Upon completion of the transaction, the company will hold a 10% equity stake in Zhongke Hongtai [1] Group 2: Product Advantages - Zhongke Hongtai's self-developed multi-channel vascular intervention surgical robot features significant advantages, including a bionic design that allows simultaneous rotation and pushing of guidewires [1] - The dual-channel design enables the operation of two guidewires and two balloon/stent catheters simultaneously, along with force feedback functionality [1] - The surgical robot can perform remote surgeries, provide full-process robotic assistance, and collect data, surpassing existing industry standards [1] Group 3: Strategic Goals - The core team of Zhongke Hongtai possesses deep technical expertise and original research capabilities, offering differentiated innovation and technological breakthroughs [2] - The investment aims to expand the company's business, enhance profitability, and improve overall competitiveness and influence, promoting sustainable development [2]